Featured news from NHIVNA
HIV-related news from NAM
Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety
Liz Highleyman, 2015-10-25 13:00:00
regimen containing the new tenofovir alafenamide (TAF) - to be marketed as Genvoya - suppressed HIV as well as a
coformulation containing the older tenofovir disoproxil fumarate (TDF),
according to a poster presented this week at the 15th
European AIDS Conference in Barcelona. A related study found that people who
switched from an atazanavir (Reyataz)
regimen to the new combination had superior virological outcomes, and in both
trials participants saw improvements in kidney and bone biomarkers.
Gilead Sciences' TAF
is a new pro-drug formulation that delivers the active agent to
HIV-infected cells more efficiently than the current TDF formulation (Viread, also
in Truvada, Atripla, Eviplera and Stribild). TDF is generally safe
and well-tolerated but it can cause a small amount of bone loss soon after
starting therapy and can lead to kidney problems in susceptible people.
Presenter Bart Rijnders from Erasmus Medical Centre in Rotterdam explained that TAF has a longer
half-life, allowing more time for active tenofovir to enter CD4 T-cells. TAF therefore produces sufficient intracellular drug
levels with a smaller dose, which means a lower concentration in the blood and
less drug exposure for the kidneys, bones, and other organs and tissues.